

News Releases

All Years



Search

GO

[Advanced Search](#)

Dec 9, 2019

Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

- Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

Dec 8, 2019

Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

- Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

Nov 15, 2019

Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

- Recommendations from Multidisciplinary Expert Panel on Anticoagulant Reversal and Replacement Guidance Published in Annals of Emergency Medicine -

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary...

Nov 6, 2019

Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

- Cerdulatinib Interim Phase 2a Data Highlight Efficacy and Safety Results in Patients with Heavily Pre-Treated T-Cell Malignancies and Follicular Lymphoma -

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will...

Nov 5, 2019

Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- Andexxa®/Ondexxya® Net Product Revenues of \$35.7 million, a 32% Increase Over the Prior Quarter -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of...

Show 5
page

< 1 2 3 4 5 6 7 8 9 ... 50 >



<https://investors.portola.com/news-releases?ID=2381753&c=198136&p=irol-newsArticle>